文献速递消化系统肿瘤

可切除局部进展期结直肠癌的新辅助免疫治疗

[Neoadjuvant immunotherapy for resectable locally advanced colorectal cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

回顾性分析32例可切除局部进展期结直肠癌患者,接受新辅助免疫治疗后行根治术,pCR率78.1%,MSI-H患者pCR率94.4%显著高于MSS患者57.1%,术后并发症25.0%,无围手术期死亡,提示安全有效。

要点

  • 新辅助免疫治疗在可切除局部进展期结直肠癌中pCR率达78.1%
  • MSI-H患者pCR率94.4%,显著高于MSS患者的57.1%
  • 术前CEA≥5 ng/ml和MSI状态与pCR相关

核心结论

  • 新辅助免疫治疗对可切除局部进展期结直肠癌安全有效。
  • MSI-H结直肠癌单独新辅助免疫治疗可获得满意结果。
  • MSS结直肠癌新辅助免疫联合常规治疗也可取得较好近期疗效。

研究设计与样本

  • 回顾性分析2019年1月至2024年2月中国医学科学院肿瘤医院32例接受新辅助免疫治疗并行根治术的局部进展期结直肠癌患者。
  • 采用Fisher精确检验进行单因素分析,Logistic回归模型进行多因素分析。

主要发现

  • 25例(78.1%)达到病理完全缓解(pCR),7例(21.9%)未达到pCR。
  • MSI-H患者pCR率为94.4%(17/18),MSS患者为57.1%(8/14),差异有统计学意义(P=0.001)。
  • 8例(25.0%)术后出现并发症,无二次手术及围手术期死亡。

关键数值与推荐

  • 术前癌胚抗原≥5 ng/ml与pCR相关(OR=0.035,95% CI:0.003~0.260,P=0.003)。
  • MSI-H和MSS POLE阳性与pCR相关(OR=19.000,95% CI:2.573~399.227,P=0.012)。

临床怎么用

  • 可切除MSI-H结直肠癌可考虑单独新辅助免疫治疗。
  • 可切除MSS结直肠癌可考虑新辅助免疫联合化疗或放化疗。
  • 术前CEA≥5 ng/ml和MSI状态可用于评估pCR可能性。

局限性

  • 回顾性分析,样本量仅32例。
  • 单中心研究,结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of resectable locally advanced colorectal cancer (LACRC) after neoadjuvant immunotherapy (IT). Methods: A retrospective analysis of the clinicopathological data of 32 patients with locally advanced colorectal cancer who received neoadjuvant immunotherapy followed by radical surgery at the Cancer Hospital Chinese Academy of Medical Sciences, from January 2019 to February 2024. Fisher's exact test was used for univariate analysis, and Logistic regression model was used for multivariate analysis. Results: Of the 32 patients, 23 were male and 9 were female; the median age was 55 years old. Seven patients with microsatellite instable-high (MSI-H) and 1 patient with microsatellite stable (MSS) received neoadjuvant immunotherapy. Eight patients received neoadjuvant immunotherapy, 16 patients (10 MSI-H and 6 MSS) received neoadjuvant chemotherapy combined with IT, and 8 patients (1 MSI-H and 7 MSS) received neoadjuvant chemoradiotherapy combined with IT. Postoperative pathological results showed that 25 patients achieved pathological complete response (pCR) (78.1%), while 7 patients did not achieve pCR (21.9%). The pCR rates were 94.4% (17/18) in MSI-H patients and 57.1% (8/14) in MSS patients, with statistically significant difference between the two groups (P=0.001). Postoperative complications occurred in 8 patients (25.0%), and there were no secondary operations or perioperative deaths. Multivariate analysis results showed that preoperative carcinoembryonic antigen (CEA) level ≥5 ng/ml(OR=0.035,95% CI:0.003~0.260, P=0.003), MSI-H and MSS POLE positive(OR=19.000,95% CI:2.573~399.227,P=0.012)were related to pCR. Conclusions: Neoadjuvant immunotherapy is safe and effective for resectable LACRC. Neoadjuvant immunotherapy alone for resectable MSI-H colorectal cancer (CRC) can achieve satisfactory results, and neoadjuvant immunotherapy in combination with various forms of conventional therapy for patients with resectable MSS CRC could also achieve better short-term effects. 目的: 分析可切除局部进展期结直肠癌新辅助免疫治疗的疗效和安全性。 方法: 回顾性分析中国医学科学院肿瘤医院2019年1月至2024年2月32例接受新辅助免疫治疗并行外科根治术的局部进展期结直肠癌患者的临床病理资料,采用Fisher精确检验进行单因素分析,Logistic回归模型进行多因素分析。 结果: 32例患者中,男23例,女9例,中位年龄55岁(27~75岁)。8例患者[7例微卫星高度不稳定(MSI-H),1例微卫星稳定(MSS)]行单纯新辅助免疫治疗,16例患者(10例MSI-H,6例MSS)行新辅助化疗联合免疫治疗,8例患者(1例MSI-H,7例MSS)行新辅助同步放化疗联合免疫治疗。术后病理结果提示,25例患者达到病理完全缓解(pCR;78.1%,25/32),7例患者未达到pCR(21.9%,7/32)。MSI-H患者中,pCR患者数为17例(17/18)。MSS患者中,pCR患者数为8例(8/14),两组间pCR率差异有统计学意义(P=0.001)。8例患者(25.0%,8/32)术后出现并发症,无二次手术及围手术期死亡患者。单因素分析结果提示,术前癌胚抗原≥5 ng/ml(OR=0.035,95% CI:0.003~0.260,P=0.003)、MSI-H和MSS POLE阳性(OR=19.000,95% CI:2.573~399.227,P=0.012)与pCR有关(均P<0.05)。 结论: 新辅助免疫治疗对于可切除的局部进展期结直肠癌是安全有效的。对可切除的MSI-H结直肠癌单独进行新辅助免疫治疗就可以获得满意的结果,对可切除MSS 结直肠癌患者进行新辅助免疫治疗与多种形式的常规治疗进行联合也可以取得较好的近期疗效。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Luo ZK, Sun Y, Xiang RS, et al. [Neoadjuvant immunotherapy for resectable locally advanced colorectal cancer]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42086526. doi:10.3760/cma.j.cn112152-20250323-00117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。